AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02791295 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet and physical activity program
Description: A personalized intervention focused on improving diet and increasing physical activity will be implemented at-home with a monthly support by a registered dietician and physical activity educator during 6 months
Study NCT03046225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous passive movement device
Description: CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
Study NCT03046225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous passive movement device
Description: CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
Study NCT03046225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
Study NCT04474860 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: gene sequencing
Description: Gene fragment analysis, Sanger sequencing method and/or high-throughput whole-genome sequencing will be performed to find the pathogenic gene and mutation site of MH in Chinese population.
Study NCT03852550 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: e-health application
Description: In the first part of this study, an e-health application (MyREADY Transition\[TM\] BBD App) was developed, targeting the needs of youth with BBD during their transition and transfer from pediatric to adult health care. Program development centered on three core foci of health care transition planning: education, empowerment, and navigation. The intervention has an emphasis on the process of transition in which youth and young adults learn information and develop skills in order to eventually assume maximal responsibility for self-management of their conditions (e.g., learning how to speak directly with health providers) while also providing information to prepare youth for the event of the transfer from pediatric to adult health care.
Study NCT01568931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urokinase
Description: intracoronary, urokinase, 200,000 Units, bolus
Study NCT01568931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: intracoronary, saline, bolus 1 cc
Study NCT00625976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded exposure in vivo
Description: Graded exposure in vivo according to the protocol of de Jong et al. (2005)
Study NCT00625976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
Study NCT03558243 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patent Hemostasis arm
Description: Patent hemostasis with TR BAND
Study NCT03558243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULTRA arm
Description: Patent hemostasis protocol plus ipsilateral ulnar compression
Study NCT03558243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemostatic disc arm
Description: StatSeal disc plus TR Band
Study NCT02306629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epratuzumab sc
Description: Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
Study NCT02306629 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epratuzumab iv
Description: Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
Study NCT01907672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid Diagnostic Test
Description: Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
Study NCT04351087 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Plasma
Description: Platelet rich plasma: 157cc of whole blood will be collected, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.~Microfragmented adipose tissue: Adipose will be aspirated from the subcutaneous tissue of the buttock or abdomen, processed, and injected into the knee joint under sterile technique using ultrasound-guidance.
Study NCT04022876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo administered IV on Days 0-2 prior to carboplatin and pemetrexed administered IV on Day 1 of every 21-day cycle.
Study NCT01120457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-936564 (Anti-CXCR4)
Study NCT03046225 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
Study NCT03163082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Intervention
Description: The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
Study NCT03163082 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
Study NCT03163082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interpretation Bias
Description: The Interpretation Bias intervention has partners look at morphed facial expressions and determine whether the face is happy or angry. Positive feedback is given for rating the faces as happy and negative feedback is given for rating the faces as angry.
Study NCT03163082 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluative Conditioning
Description: The Evaluative Conditioning intervention presents partners with pictures of ambiguous adult faces (conditioned stimuli) and pairs them with positive word descriptors (unconditioned stimuli; e.g., generous; loving).
Study NCT03603444 — intervention group
Intervention type: OTHER
Intervention: No intervention are provided
Study NCT01591876 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intradialytic aerobic exercise
Description: Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.
Study NCT01591876 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Progressive Muscle relaxation
Description: This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
Study NCT02556333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TAF
Description: Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
Study NCT00056563 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Deep Brain Stimulation
Description: The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
Study NCT00056563 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: best medical therapy
Description: Participants will initially be randomized to DBS or to 6 months of best medical therapy. BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months.
Study NCT01632969 — intervention group
Intervention type: BEHAVIORAL
Intervention: The The Family Assessment of Treatment at the End of life (FATE ) survey
Description: Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
Study NCT03444922 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ingestion of Placebo
Study NCT03444922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPA 4 ug/kg BW
Description: Oral BPA ingestion of 4 ug/kg BW
Study NCT03444922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPA 50 ug/kg BW
Description: Oral BPA ingestion of 50 ug/kg BW
Study NCT02401880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: 22 subjects will receive Linagliptin for 30 days
Study NCT01274507 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Medical tests
Description: All participants will undergo medical tests and will be observed.
Study NCT04022876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALRN-6924
Description: ALRN-6924 administered IV on Days 0-4 prior to topotecan administered IV on Days 1-5 of every 21-day cycle.
Study NCT04022876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan administered IV on Days 1-5 of every 21-day cycle.
Study NCT02401880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 22 subjects will receive Placebo for 30 days
Study NCT04291625 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Levator muscle resection
Description: Surgery was performed under general anaesthesia. Two milliliters of 2% lidocaine with 1:100 000 epinephrine is injected subcutaneously. After the upper eyelid incision at the desired crease line, the orbital septum was opened and the preaponeurotic fat was identified and dissected off the levator aponeurosis. The aponeurosis was disinserted from the tarsus, and the complex of levator aponeurosis and Muller muscle was dissected free from the conjunctiva. The desired eyelid height was determined from the proposed formula.~Satisfactory Intraoperative lagophthalmos was defined as a difference of less than 1 mm between recommended by the formula and actual intraoperative lagophthalmos.~After permanent fixation, a caliper was used for precise measurement of lagophthalmos in a supine position. Additional sutures were placed on the medial and lateral sides for satisfactory eyelid contour. The redundant levator complex was excised. Eyelid crease was made by placing three interrupted sutures
Study NCT02468050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training
Description: 6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.
Study NCT02468050 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Management of exercise
Description: In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
Study NCT02660905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E/C/F/TAF;
Description: Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
Study NCT02660905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir-Sofosbuvir
Description: Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
Study NCT02115620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
Study NCT03782766 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Piezocision
Description: Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
Study NCT03782766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Piezocision
Description: Piezocesion was performed by making 2 vertical incisions mesial and distal to the extraction space. Piezotome was inserted in the incisions previously made and bone cuts were done with a length up to mucogingival line and depth of 3 mm.
Study NCT01193361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
Study NCT01193361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-791325
Description: Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
Study NCT02401880 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Empagliflozin
Description: 44 subjects will receive Empagliflozin for 60 days
Study NCT02401880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin
Description: 44 subjects will receive Empagliflozin for 60 days
Study NCT02401880 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Empagliflozin
Description: 44 subjects will receive Empagliflozin for 60 days
Study NCT02235142 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT04357015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous tranexamic acid
Description: The tranexamic acid (TXA) group will receive a single bolus IV injection of 15 mg/kg of TXA 20 minutes before surgical incision
Study NCT04357015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous carbetocin
Description: The carbetocin group will receive a single bolus IV injection of 100 mcg of carbetocin 20 minutes before surgical incision
Study NCT04357015 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the placebo group will be given a normal saline IV bolus 20 minutes before surgical incision
Study NCT01193361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
Study NCT01193361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-interferon alfa-2a
Description: Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
Study NCT01193361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peg-interferon alfa-2a
Description: Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
Study NCT01193361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
Study NCT01193361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
Study NCT00697424 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SleepStyle 200 Auto Series CPAP Humidifier
Description: The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
Study NCT04488406 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: Not applicable to these subjects. There is no study-related intervention
Study NCT01272245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omacetaxine
Description: 1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
Study NCT01272245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: 20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
Study NCT00143039 — intervention group
Intervention type: PROCEDURE
Intervention: Tandem MS test for inborn errors of metabolism
Description: Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
Study NCT02058186 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral vitamin D
Study NCT02058186 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03907085 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HILT + exercise
Description: High intensity laser therapy-Patients received pulsed laser treatment, using a HIRO 3 device (ASA Laser, Arcugnano, Italy), five times a week for a period of three weeks, and one session per day for a total of 15 sessions. A 3-phase treatment program was performed in each session, and the patients were then given a daily exercise program once a day by a physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
Study NCT03907085 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo HILT + exercise
Description: Placebo HILT group; Placebo therapy was applied in five sessions a week for three weeks, with a total of 15 sessions a day, with no current flowing through the device. This was followed by the exercise programs described above, performed once a day with the physiotherapist. Exercise program; A physiotherapist-assisted exercise program was performed by the two groups, five times a week for three weeks, for approximately 25 minutes. The exercise programs consisted of stretching exercises to the plantar fascia and Achilles tendon, active range of motion (ROM) exercises, and strengthening exercises to the tibialis posterior and peroneus muscles. The patients were also taught to collect the foot and towel.
Study NCT01611558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT02705339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rociletinib
Study NCT02705339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Standard of care biopsies will be taken at diagnosis and at the time of disease progression
Study NCT02705339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: -Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
Study NCT01165268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Tablets, Oral, 10 mg, Once daily, 7 days
Study NCT01739192 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: Subjects will be maintained on oral bupropion or placebo during the study.
Study NCT04195386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental Restoration with Chemically activated Composite resin Alkasite
Description: Selective removal of dental caries with manual instruments, under relative isolation, application of universal adhesive system and restoration with chemically activated composite resin Alkasite.
Study NCT04195386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Restoration with Resin-Modified Glass ionomer Cement
Description: Selective removal of dental caries with manual instruments, under relative isolation, application of polyacrylic acid and restoration with resin-modified glass ionomer cement.
Study NCT04039152 — intervention group
Intervention type: OTHER
Intervention: locally adapted neonatal sepsis treatment protocol
Description: the neonatal sepsis treatment protocol was modified according to the local antibiotics susceptibility patterns
Study NCT00536952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme
Description: Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer